Jane Street
BCLI

Jane Street’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Jane Street’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-793
Closed -$39K – 10051
2021
Q3 		$39K Sell
793
-527
-40% -$27.7K ﹤0.01% 9620
2021
Q2 		$75K Sell
1,320
-2,047
-61% -$109K ﹤0.01% 9381
2021
Q1 		$193K Sell
3,367
-806
-19% -$60.9K ﹤0.01% 8298
2020
Q4 		$283K Buy
4,173
+3,506
+526% +$477K ﹤0.01% 6495
2020
Q3 		$169K Buy
+667
New +$137K ﹤0.01% 6527

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $488M AUM 17.59% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Jane Street's BCLI Position: Q3 2024 in Review

Jane Street sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q3 2024, closing a stake of 1,322 shares — an estimated $6.71K sold.

Jane Street first reported a position in BCLI in Q1 2020 and held it in 9 quarters. The position peaked at $173K in Q4 2020. 38 funds tracked by Wall St. Rank hold BCLI as of Q3 2024.

  • Jane Street reported no remaining BRAINSTORM CELL THERAPUTC position as of Q3 2024 after selling out during the quarter.
  • Jane Street sold 1,322 BRAINSTORM CELL THERAPUTC shares in Q3 2024, an estimated $6.71K.
  • Jane Street first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 9 quarters.
  • Jane Street's BRAINSTORM CELL THERAPUTC position peaked at $173K in Q4 2020.
  • 38 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q3 2024.

Based on Jane Street's 13F filing for Q3 2024, filed 15 Nov 2024.